We are live on ! Find out more
ACAD icon

Acadia Pharmaceuticals
ACAD

123 hedge funds and large institutions have $1.5B invested in Acadia Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 123 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

433% more call options, than puts

Call options by funds: $237M | Put options by funds: $44.5M

92.92% more ownership

Funds ownership: 0% → 92.92% (+93%)

Holders
123
Holders Change
+123
Holders Change %
–
% of All Funds
4%
Holding in Top 10
7
Holding in Top 10 Change
+7
Holding in Top 10 Change %
% of All Funds
0.23%
New
123
Increased
–
Reduced
–
Closed
–
Calls
$237M
Puts
$44.5M
Net Calls
+$193M
Net Calls Change
+$193M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

ACAD Hedge Fund Activity: Q2 2013 in Review

123 of the 3,075 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q2 2013, worth a combined $1.5B.

Buyers outnumbered sellers: 123 funds opened new ACAD positions and 0 closed out — a net gain of 123 holders — while 0 added to existing stakes and 0 trimmed.

  • 123 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $1.5B of Acadia Pharmaceuticals stock for Q2 2013.
  • 123 funds opened new Acadia Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +123 holders.

Based on aggregated 13F filings for Q2 2013.